Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

Kidney Int Rep. 2021;7(3):516-525 doi: 10.1056/NEJMoa2106535

Iberdomide is a cereblon modulator that promotes degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development and autoimmunity. In this Phase 2 trial, was evaluated for the treatment of SLE. Patients were randomly assigned in a 2:2:1:2 ratio to receive oral iberdomide at a dose of 0.45, 0.30, or 0.15 mg, or placebo once daily for 24 weeks. A higher percentage of patients receiving iberdomide 0.45 mg achieved SRI-4 response than those receiving placebo.